AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early breast cancer in two pivotal clinical trials.
First, in another major head-to-head win against Roche’s rival antibody-drug conjugate Kadcyla, Enhertu significantly pared down the risk of invasive disease recurrence or death by 53% when used as an adjuvant therapy after surgery in HER2-positive early breast cancer. The patients had residual invasive disease following neoadjuvant treatment and are considered at high risk of recurrence.
At the time of the analysis, 12.5% of patients who got Kadcyla have developed invasive disease or died, versus 6.2% among Enhertu takers. The data, from the Destiny-Breast05 study, will be presented during a presidential symposium at the 2025 European Society for Medical Oncology Congress.
